Chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter?

Jules L. Derks, Robert Jan van Suylen, Erik Thunnissen, Michael A. den Bakker, Harry J. Groen, Egbert F. Smit, Ronald A. Damhuis, Esther C. van den Broek, Ernst-Jan M. Speel, Anne-Marie C. Dingemans*, PALGA Grp

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Article number1601838
Number of pages9
JournalEuropean Respiratory Journal
Volume49
Issue number6
DOIs
Publication statusPublished - Jun 2017

Keywords

  • MULTICENTER-PHASE-II
  • LUNG-CANCER
  • CLINICAL-PRACTICE
  • CISPLATIN
  • TUMORS
  • CARBOPLATIN
  • IRINOTECAN
  • DIAGNOSIS
  • FEATURES
  • OUTCOMES

Cite this

Derks, J. L., van Suylen, R. J., Thunnissen, E., den Bakker, M. A., Groen, H. J., Smit, E. F., Damhuis, R. A., van den Broek, E. C., Speel, E-J. M., Dingemans, A-M. C., & PALGA Grp (2017). Chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter? European Respiratory Journal, 49(6), [1601838]. https://doi.org/10.1183/13993003.01838-2016